ProCE Banner Activity

Expert Answers to FAQ on Neo/Adjuvant Therapy in Early Breast Cancer

Clinical Thought

In this commentary, I answer audience questions from a live satellite symposium at SABCS 2022 on the expanding role of biomarkers in guiding neoadjuvant and adjuvant therapy for early breast cancer.

Released: February 07, 2023

Expiration: February 06, 2024

No longer available for credit.



Joyce O'Shaughnessy

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

AstraZeneca Pharmaceuticals


Merck Sharp & Dohme, LLC



Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bayer, Bristol-Myers Squibb, Carrick, Celgene, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme, Heron, Immunomedics, Ipsen, Lilly, Merck, Myriad, Nektar, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax, Synthon, Taiho Oncology, Takeda.